Skip to main content
SpringerLink
Log in

Marijuana and Cannabinoids for Pain

  • Chapter
  • First Online:
Controlled Substance Management in Chronic Pain

Abstract

Cannabis has been used as medicine and for its mind-altering qualities for centuries.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr. 2006;28:153–7.

    Article  PubMed  Google Scholar 

  2. Amar MB. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105:1–25.

    Article  PubMed  Google Scholar 

  3. Kalant H. Medicinal use of cannabis: history and current status. Pain Res Manage. 2001;6:80–91.

    Article  CAS  Google Scholar 

  4. Mikuriya TH. Marijuana in medicine: past, present and future. Calif Med. 1969;110:34–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Wood GB, Bache F. The dispensatory of the United States of America. 6th ed. Philadelphia: Grigg and Elliot; 1845. p. 1238.

    Google Scholar 

  6. Aldrich M. History of therapeutic cannabis. In: Mathre ML, editor. Cannabis in medical practice. Jefferson, NC: Mc Farland; 1997. p. 35–55.

    Google Scholar 

  7. Sofia RD, et al. Antiedema and analgesic properties of D9 tetrahydrocannabinol. J Pharmacol Exp Ther. 1973;186:646–54.

    CAS  PubMed  Google Scholar 

  8. Kosersky DS, Dewey WL, Harris L. Anitpyretic analgesic and antiinflammatory effects of delt 9-tetrahyodrocannabinol in the rat. Eur J Pharmacol. 1973;24:1–7.

    Article  CAS  PubMed  Google Scholar 

  9. Bloom AS, et al. 9-Nor-9B-hydroxyhexahydrocannabinol a cannabiniod with potent antinociceptive activity: comparisons with morphine. J Phamacol Exp Therap. 1977;200:263–70.

    CAS  Google Scholar 

  10. Cravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol. 2004;61:149–60.

    Article  CAS  PubMed  Google Scholar 

  11. Joy JE, Watson SJ, Benson JA. Marijuana and medicine: assessing the science base. Institute of Medicine National Academy Press; 1999.

    Google Scholar 

  12. Pertwee RG. Pharmacological actions of cannabinoids. HEP. 2005;168:1–51.

    CAS  Google Scholar 

  13. Elikottil J, Gupta P, Gupta K. The analgesic potential of cannabinoids. J Opioid Manag. 2009;5:341–57.

    PubMed  PubMed Central  Google Scholar 

  14. Robson PJ. Therapeutic potential of cannabinoid medicines. Drug Text Anal. 2014;6:24–30.

    Article  CAS  Google Scholar 

  15. Mechmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, Ross SA, Khan IA, ElSohly MA. Potency trends of delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993–2008. J Forensic Sci. 2010;55:1209–17.

    Article  Google Scholar 

  16. Appendino G, Chianese G, Taglialatela-Scafati O. Cannabinoids: occurrence and medicinal chemistry. Curr Med Chem. 2011;18:1085–99.

    Article  CAS  PubMed  Google Scholar 

  17. Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacother. 2013;33:192–209.

    Article  Google Scholar 

  18. ElSohly MA. Quarterly report potency monitoring project. Report 104. In: NIDA Marijuana Project, National center for natural products research division of the resean institute of pharmaceutical sciences. The School of Pharmacy, University of Mississippi; 2009.

    Google Scholar 

  19. El Sohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF. Potency trends of delta 9-THC and other cannabinoids in confiscated marijuana from 1980–1997. J Forensic Sci. 2000;45:24–30.

    Google Scholar 

  20. Maa E, Figi P. The case for medical marijuana in epilepsy.y. Epilepsia. 2014;55:783–6.

    Article  PubMed  Google Scholar 

  21. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta-9-tetrahydrocanabidiol, cannabidiol and delta-9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199–215.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, Egawa T, Kitamura Y, Uchida N, Nishimura R, Egashira N, Iwasaki K, Fujiwara M. Cannabidiol potentiates pharmacological effects of delta-9-tetrahydrocannabinol via CB1 receptor-dependent mechanism. J Brain Res. 2008;1188:157–64.

    Article  CAS  Google Scholar 

  23. Russo EB, Guy GW. A tale of two cabanninoids: the therapeutic rationale for combining tetrahydrocannibinol and cannabidiol. Med Hypotheses. 2006;66:234–46.

    Article  CAS  PubMed  Google Scholar 

  24. Mahadevan A, Siegel C, Martin BR, Abood ME, Beletskaya I, Razdan RK. Novel cannabinol probes for CB1 and CB2 cannabinoid receptors. J Med Chem. 2000;43:3778–85.

    Article  CAS  PubMed  Google Scholar 

  25. Robson P. Human studies of cannabinoids and medicinal cannabis. HEP. 2005;168:719–56.

    CAS  Google Scholar 

  26. Di Marzo V, De Petrocellis L. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med. 2006;57:553–74.

    Article  PubMed  Google Scholar 

  27. Burstein SH, Tepper MA. In vitro metabolism and metabolic effects of ajulemic acid, a synthetic cannabinoid agonist. Pharma Res Per. 2013;1:1–9.

    Google Scholar 

  28. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;53:389–462.

    Article  Google Scholar 

  29. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord: Drug Targets. 2009;8:403–21.

    Article  CAS  Google Scholar 

  30. Rice ASC, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids. 2002;66:243–56.

    Article  CAS  PubMed  Google Scholar 

  31. La Porta C, Bura SA, Negrete R, Maldonado R. Involvement of the endocannabinoid system in osteoarthritis pain. Eur J Neuroscience. 2014;39:485–500.

    Article  Google Scholar 

  32. Davis MP. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. Expert Opin Invest Drugs. 2014;23:1123–40.

    Article  CAS  Google Scholar 

  33. Lichtman AH, Martin BR. Spinal and supraspinal mechanisms of cannabinoid-induced antinociception. J Pharmacol Exp Ther. 1991;258:517–23.

    CAS  PubMed  Google Scholar 

  34. Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther. 1996;276:585–93.

    CAS  PubMed  Google Scholar 

  35. Monhemius R, Azami J, Green DL, Roberts MH. CB1 receptor mediated analgesia from the nucleus reticularis gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Res. 2001;908:67–74.

    Article  CAS  PubMed  Google Scholar 

  36. Yaksh TL. The antinociceptive effects of intrathecally administered levoantradol and deacetyllevonatradol in the rat. J Clin Pharmacol. 1981;21:334S–40S.

    Article  CAS  PubMed  Google Scholar 

  37. Smith FL, Fujimori K, Lowe J, Welch SP. Characterization of delta-9-tetrahydrocannabinol and anadamide antinociception in nonarthritic and arthritic rats. Parmacol Biochem Behav. 1998;60:183–91.

    Article  CAS  Google Scholar 

  38. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain. 1998;75:111–9.

    Article  CAS  PubMed  Google Scholar 

  39. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 1998;394:277–81.

    Article  CAS  PubMed  Google Scholar 

  40. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci. 1999;96:12198–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H, Mackie K, Faull KF, Spigelman I. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain. 2006;126:102–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Stander S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci. 2005;38:177–88.

    Article  PubMed  Google Scholar 

  43. de Meijer E. The breeding of cannabis cultivars for pharmaceutical end uses. In: Guy GW, Whittle BA, Robson P, editors. Medicinal uses of cannabis and cannabinoids. London: Pharmaceutical Press; 2004. p. 55–70.

    Google Scholar 

  44. Borgelt LM, Franson KL, Nussbaoum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacother. 2013;33:195–209.

    Article  CAS  Google Scholar 

  45. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327–60.

    Article  CAS  PubMed  Google Scholar 

  46. Agurell S, Halldin M, Lindgren JE. Pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986;38:21–43.

    CAS  PubMed  Google Scholar 

  47. Elikottil J, Gupta P, Gupta K. The analgesic potential of cannabinoids. J Opioid Manag. 2009;5:341–57.

    PubMed  PubMed Central  Google Scholar 

  48. Ellis GM, Mann MA, Judson BA, Schramm NT, Tashchian A. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther. 1985;38:572–8.

    Article  CAS  PubMed  Google Scholar 

  49. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology. 1982;76:245–50.

    Article  CAS  PubMed  Google Scholar 

  50. Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011;57:66–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev. 2007;17:347–61.

    Article  PubMed  Google Scholar 

  52. Hall W, Degenhardt L. Cannabis use and psychosis: a review of clinical evidence and epidemiological evidence. Aust NZ J Psychiatry. 2000;34:26–34.

    Article  CAS  Google Scholar 

  53. Wang T, Collet JP, Shapiro S, Ware M. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178:1669–78.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Gonzalez R, Carey C, Grant I. Nonacute (residual) neuropsychological effects of cannabis use: a qualitative analysis and systematic review. J Clin Pharm. 2002;42:48S–57S.

    Article  CAS  Google Scholar 

  55. Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc. 2003;9:679–89.

    Article  CAS  PubMed  Google Scholar 

  56. Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. Drug Test Anal. 2014;6:39–45.

    Article  CAS  PubMed  Google Scholar 

  57. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonlad K, Ward A, Poulton R, Moffitt TE. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA. 2012;109:E2657–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Horwood L, Fergusson D, Hayatbakhsh M, Najman J, Coffey C, Patton G, Silins E, Hutchinson DM. Cannabis use and educational achievement: findings from three Australian cohort studies. Drug Alcohol Depend. 2010;110:247–53.

    Article  PubMed  Google Scholar 

  59. Rogeberg O. Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding from socioeconomic status. Proc Natl Acad Sci. 2013;110:4251–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Gordon AJ, Conley JW, Gordon JM. Medical consequences of marijuana use: a review of current literature. Curr Psychiatry Rep. 2013;15:419.

    Article  PubMed  Google Scholar 

  61. Hancoz RJ, Poulton R, Ely M, Welch D, Taylor DR, McLachian CR, Greene JM, Moffitt TE, Caspi A, Sears MR. Effects of cannabis on lung function: a population-based cohort study. Eur Respir J. 2010;35:42–7.

    Article  Google Scholar 

  62. Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory compliance: a systematic review. Arch Intern Med. 2007;167:221–8.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Aldington S, Williams M, Nowitz M, Weatherall M, Prichard A, McNaughton A, Robinson G, Beasley R. Effects of cannabis on pulmonary structure, function and symptoms. Thorax. 2007;62:1058–63.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Wu TC, Tashkin DP, Djahed B, Rose JE. Pulmonary hazards of smoking marijuana as compared with tobacco. NEJM. 1988;318:347–51.

    Article  CAS  PubMed  Google Scholar 

  65. Relman AS. Committee to study the health-related effects of cannabis and its derivatives. Marijuana and health. Washington, DC: Institute of Medicine, National Academy Press; 1982. p. 16–8.

    Google Scholar 

  66. Bundy AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry. 2006;19:233–8.

    Article  Google Scholar 

  67. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther. 2002;95:127–35.

    Article  CAS  PubMed  Google Scholar 

  68. Greenwald MK, Stitzer ML. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend. 2000;59:261–75.

    Article  CAS  PubMed  Google Scholar 

  69. Milstein SL, MacCannell K, Karr G, Clark S. Marijuana-produced impairments in coordination. Experienced and nonexperienced subjects. J Nerv Ment Dis. 1975;161:26–31.

    Article  CAS  PubMed  Google Scholar 

  70. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain. 2003;105:79–88.

    Article  CAS  PubMed  Google Scholar 

  71. Zeidenberg P, Clark WC, Jaffe J, Anderson SW, Chin S, Malitz S. Effect of oral administration of delta-9-tetrahydrocannabinol on memory, speech, and perception of thermal stimulation: results with four normal human volunteer subjects. Compr Psychiatry. 1973;14:549–56.

    Article  CAS  PubMed  Google Scholar 

  72. Hill SY, Schwin R, Goodwin DW, Powell BJ. Marihuana and pain. J Phamacol Exp Ther. 1974;188:415–8.

    CAS  Google Scholar 

  73. Clark WC, Janal MN, Zeidenberg P, Nahas GG. Effects of moderate and high doses of marihuana on thermal pain: a sensory decision theory analysis. J Clin Pharmacol. 1981;21:299S–310S.

    Article  CAS  PubMed  Google Scholar 

  74. Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, Gouaux B, Abramson I. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology. 2007;107:785–96.

    Article  PubMed  Google Scholar 

  75. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68:515–21.

    Article  CAS  PubMed  Google Scholar 

  76. Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, Kress HG. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology. 2008;109:101–10.

    Article  PubMed  Google Scholar 

  77. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson T. Meta-anlysis of cannabis based treatements for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007;23:17–24.

    Article  CAS  PubMed  Google Scholar 

  78. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain. 2004;112:299–306.

    Article  PubMed  Google Scholar 

  79. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterized by allodynia: a randomized, double-blind, placebo-controlled clinical trial. Pain. 2007;133:210–20.

    Article  CAS  PubMed  Google Scholar 

  80. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68:515–21.

    Article  CAS  PubMed  Google Scholar 

  81. Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H, Atkinson JH. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34:672–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Ware MA, Wang T, Shapiro S, Robinson A, Ducret T, Huynh T, Gamsa A, Bennett GJ, Collet JP. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010;182:E694–701.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A randomized, placebo controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9:506–21.

    Article  CAS  PubMed  Google Scholar 

  84. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812–9.

    Article  PubMed  Google Scholar 

  85. Zajicek JP, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A. Cannabinoids for treatment of spasticiy and other symptoms related to multiple sclerosis (CAMS study): multicenter randomized placebo-controlled trial. Lancet. 2003;362:1517–26.

    Article  CAS  PubMed  Google Scholar 

  86. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434–41.

    Article  CAS  PubMed  Google Scholar 

  87. Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. Systematic review: Efficacy and safety of medical marijuana in selected neurological disorders. Report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556–63.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Moulin DE, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-Forster PK, Sessle BJ, Squire P, Stinson J, Taenzer P, Velly A, Ware MA, Weinberg EL, Williamson OD. Pharmacological management of chornic neuropathic pain: revised consensus statement from the canadian pain society. Pain Res Manag. 2014;19:328–35.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Noyes R, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol. 1975;15:139–43.

    Article  PubMed  Google Scholar 

  90. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39(2):167–79.

    Article  PubMed  Google Scholar 

  91. Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, Fallon MT. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–49.

    Article  CAS  PubMed  Google Scholar 

  92. Hirschler B. GW Pharma’s cannabis drug fails in cancer pain study, shares fall. Reuters.com. 8 Jan 2015. http://www.reuters.com/article/2015/01/08/us-gw-pharma-epilepsy-idUSKBN0KH13U20150108

  93. Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology. 2006;104:1040–6.

    Article  CAS  PubMed  Google Scholar 

  94. Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003;106:169–72.

    Article  CAS  PubMed  Google Scholar 

  95. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth. 2006;53:769–75.

    Article  PubMed  Google Scholar 

  96. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison RN. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008;9:254–64.

    Article  CAS  PubMed  Google Scholar 

  97. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology. 2006;45:50–2.

    Article  CAS  PubMed  Google Scholar 

  98. Grant I, Atkinson H, Gouaux B, Wilsey B. Medical marijuana: clearing away the smoke. Open Neurology Journal. 2012;6:18–25.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Physician recommendation of medical cannabis: guidelines of the council on scientific affairs subcommittee on medical marijuana practice advisory. Rev Aug 2011. California Medical Association. http://www.mbc.ca.gov/Licensees/Prescribing/medical_marijuana_cma-recommend.pdf

  100. Wilsey B, Atkinson JH, Marcotte TD, Grant I. The medicinal cannabis treatment agreement: providing information to chronic pain patients through a written document. Clin J Pain. 2015;31(12):1087–96.

    Article  PubMed  Google Scholar 

  101. Robson P. Abuse potential and psychoactive effects of Delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf. 2011;10:675–85.

    Article  CAS  PubMed  Google Scholar 

  102. 23 Legal marijuana states and DC. @ Pro-Con.org http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology, UC San Diego Medical Center, 9300 Campus Point Drive, Mail Code 7651, San Diego, CA, 92037, USA

    Timothy Furnish

  2. Department of Anesthesiology, University of California San Diego, 9300 Campus Point Drive, 7651, La Jolla, CA, 92037, USA

    Mark Wallace

Authors
  1. Timothy Furnish
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Wallace
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Wallace .

Editor information

Editors and Affiliations

  1. Shrewsbury, New Jersey, USA

    Peter S. Staats

  2. Comprehensive Pain Medicine, Pompano Beach, Florida, USA

    Sanford M. Silverman

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Furnish, T., Wallace, M. (2016). Marijuana and Cannabinoids for Pain. In: Staats, P., Silverman, S. (eds) Controlled Substance Management in Chronic Pain. Springer, Cham. https://doi.org/10.1007/978-3-319-30964-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-30964-4_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-30962-0

  • Online ISBN: 978-3-319-30964-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation